CompletedPhase 2NCT00992771
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
Studying Rare genetic neurological disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of South Florida
- Principal Investigator
- Theresa Zesiewicz, MD, MDUniversity of South Florida
- Intervention
- varenicline(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2009 – 2011
Study locations (3)
- University of California - Los Angeles, Los Angeles, California, United States
- University of Florida, Gainesville, Florida, United States
- University of South Florida, Tampa, Florida, United States
Collaborators
National Ataxia Foundation · Bob Allison Ataxia Research Center (BAARC) · Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00992771 on ClinicalTrials.gov